NCT06847698View on ClinicalTrials.gov

Single Ascending Dose and Multiple Ascending Dose Study of AVR-48

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions

Safety IssuesTolerabilityPharmacokineticsPharmacodynamics

Interventions

DRUG

AVR-48

Investigational drug reconstituted in normal saline will be administered via IV

DRUG

Placebo

Normal saline will be administered via IV

Trial Locations (1)

78744

PPD, Austin

Sponsors

Lead Sponsor

AyuVis Research, Inc.

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

lead

AyuVis Research, Inc.

INDUSTRY